Movement as medicine: new evidence on exercise and cancer outcomes
Structured exercise may do more for people with cancer than ease fatigue and improve day-to-day functioning. A new synthesis of the available evidence concludes that patients who take part in organized exercise programs as part of their care appear to live longer and spend more time free of disease.
The review was published online in the British Journal of Sports Medicine. Its authors pooled data from randomized controlled trials conducted across four continents and report that the association held across several measures of survival and recurrence, prompting them to argue that the therapeutic potential of exercise deserves serious consideration within routine cancer care.
How the researchers built the evidence base
To strengthen what has been a contested area, the investigators searched research databases for randomized controlled clinical trials published up to the end of 2025. Eligible studies had to report on survival and disease recurrence in adults with confirmed cancer who were given structured exercise programs as part of their treatment.
An initial pool of 123 studies was narrowed to 21 clinical trials that met the eligibility criteria. Those trials were carried out in North America, Europe, Australia and Asia and involved a total of 8,449 participants.
- Participants: 8,449 adults, 88% of them women
- Average age: 54 years, with a range from 47 to 76
- Average monitoring period: 64 months, ranging from 2 to 99 months
- Most studied tumor types: breast cancer first, followed by bowel and pancreatic cancers
Because the analysis combined results from multiple trials rather than following a single group of patients, it offers a broader view of the question than any one study could provide on its own.
The headline numbers
When the trial results were pooled, structured exercise was associated with meaningful improvements in overall survival. Compared with patients who did not exercise as part of their care, those who did were 23% less likely to die and 17% less likely to experience a recurrence before death.
Separate analyses broke the mortality picture down further. Patients who exercised were 18% less likely to die from any cause and 26% less likely to die from their cancer specifically.
The pattern is consistent across the outcomes the researchers examined: the direction of benefit pointed the same way each time, even as the size of the effect varied depending on how the endpoint was defined.
Who appeared to gain the most
Not every subgroup benefited to the same degree, and the review highlights three factors that coincided with the strongest survival and recurrence risk advantages.
Early stage disease
The benefits were most pronounced in patients whose cancer was diagnosed at an early stage, suggesting that exercise may be most useful when it is introduced earlier in the treatment trajectory rather than reserved for advanced disease.
Aerobic training, alone or combined with strength work
Programs built around aerobic exercise, or aerobic exercise plus strength training, showed the clearest links to better outcomes. That combination format — cardiovascular conditioning paired with resistance work — recurred across the trials that demonstrated the largest advantages.
Sticking with the routine
Adherence mattered. Patients who managed to keep up their exercise routines over time saw stronger benefits than those whose participation lapsed, underscoring that consistency, not merely enrollment in a program, appears to drive the association.
Why recurrence is the central concern
The stakes are high because cancer returns in 20% to 40% of patients even after standard curative surgery and chemotherapy. That window — after apparently successful treatment but before any sign of relapse — is precisely where interventions that could delay or prevent recurrence would have the greatest value.
Structured exercise is already widely recommended during and after cancer treatment. Its established roles include reducing fatigue and improving physical functioning and quality of life. What has remained a matter of debate is whether the same activity can also alter the disease course itself, extending survival or postponing recurrence. This review was designed to address that question directly by pooling the randomized trial evidence rather than relying on individual studies or observational data alone.
Caveats worth keeping in mind
Several features of the evidence base shape how the findings should be interpreted.
First, the participant pool skewed heavily toward women — 88% of the total — and breast cancer was the most frequently studied diagnosis. Results may not translate identically to cancers that were represented by fewer trials, such as pancreatic or bowel cancer.
Second, the trials varied widely in how long patients were monitored, from as little as two months to more than eight years, and the exercise programs themselves differed in format, intensity and duration. Pooling heterogeneous studies can smooth out those differences.
Third, the authors note that not every endpoint produced a clear signal. While the survival and recurrence figures were significant, the review did not find clear evidence that structured exercise lengthened one of the other intervals the researchers examined. That absence of a clear result is a reminder that the picture is not uniformly positive across every measure.
Finally, even within randomized trials, participants who adhere to an exercise program may differ systematically from those who do not in ways that are difficult to fully account for.
What this means for cancer care
The researchers conclude that incorporating the therapeutic potential of exercise into cancer care merits consideration. In practical terms, that points toward treating physical activity not simply as supportive care for symptoms, but as a component of treatment planning that is prescribed, monitored and adjusted over time.
Key takeaways
- Pooled data from 21 randomized trials and 8,449 patients link structured exercise to better survival and lower recurrence risk.
- Patients who exercised were 23% less likely to die and 17% less likely to have a recurrence before death.
- Cause-specific analyses showed an 18% lower risk of death from any cause and a 26% lower risk of dying from cancer.
- Advantages were strongest in early stage disease, with aerobic exercise or aerobic plus strength training, and among those who maintained their routines.
- The authors argue that exercise's therapeutic potential belongs in the broader conversation about cancer treatment.
For patients and clinicians, the message is not that a workout replaces surgery, chemotherapy or radiation, but that structured activity may be a meaningful addition to the standard treatment pathway — particularly when it starts early and continues consistently.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
